20
B-CLL IS A CONDITION OF AGING:
AN EDITORIAL COMMENT
 
WH ADLER
 
    My proposal is simply that B-cell Chronic Lymphocytic Leukemia is not a disease, it is a condition, and specifically it is a condition of aging. My reasons for proposing this are that all that I heard at the meeting about the Cells, the Patients, the Disease, and the Risk Factors brought me back to things which we consider to be part of normal human aging. The major difference between a “condition” and a “disease” is going to be the incidence and I'll get to that in a moment.
 
    With aging the following features are well documented (see Ref. 1 for a general review of aging and immune function in humans): A limitation in the use of the Variable Heavy Chain Genes by B-cells. A loss of heterogeneity in the immune response with a limitation in the avidity and specificity of the antibody (2). A decrease in the proliferative ability of the lymphocyte with more cells residing in the G0 and G2 parts of the cell cycle (3,4).
 
    A marked increase in the synthesis and release of TGF-b is noted with aging (5). This is seen in humans and mice, in vivo and in vitro. It occurs in the absence of any added stimulant such as endotoxin LPS but can be boosted with LPS and ConA. It may be linked to abnormalities in receptor expression but can be shown to be an inhibitor of proliferation by interacting with the
p21 protein that controls the cdc kinase system.
 
    Benign monoclonal gammopathies appear in the elderly (6), as do autoimmune antibodies (7). About 10% of people over age 70 will have Rheumatoid Factor. Disruptions in the pattern of lymphokine synthesis occurs with a decrease in the T cell growth factors such as IL-2, and an increase in the amounts of IL-6, TNF, TGF, IFNg, and IL-4 which can encourage B-cell growth
(8). There are also gender differences in the types of B-cells in the circulation (9).

    B-CLL is not a fatal disease in many people. Risk factor analysis points to age as the most important variable. In fact with age factored out or corrected for, no other major risk factor appears. Loss of B-cell function and all the various B-cell abnormalities listed above occur without an identifiable B-cell defect(s). All the B-cell problems seen in aging seem to be related to a loss of T cell control. Thymic involution and loss of T cell function is age related.  Most individuals over age 60 have marginal T cell function.
 
    Therefore it would seem to me that you are not dealing with a disease.  There are many features of aging that are “conditions” rather than “diseases”.  Hair loss, wrinkles, menopause, weight gain, thymic involution, loss of T cell mediated immunity, and glucose metabolic abnormalities are not considered to be diseases. A major difference between a condition and a disease is going to be the incidence. Based on the assumption that B-CLL is a condition of aging I would predict that you will find a lot more “abnormal” B-cells in a larger part of the elderly population than you might expect. It may well be a relatively common finding, far in excess of the reported disease incidence rate for B-CLL. This will make patient population selection very important, and comparisons of young versus old patients may be instructive.
 

REFERENCES
 
  1. Adler WH, Nagel JE: Clinical Immunology and Aging. In Principles of Geriatric Medicine,
      and Gerontology Third Edition, WR Hazzard, EL Bierman, JP Blass, WH Ettinger, JB
      Halter, and R Andres Eds., McGraw-Hill, New York 1994; 61-75.
  2. Schulze DH; Goidl EA Age-associated changes in antibody-forming cells (B-cells).Proc Soc
      Exp Biol Med 1991; Mar;196(3):253-9
  3. Adler WH, Nagel JE. Studies of Immune Function in a Human Population.  In
      Immunological Aspects of Aging, D Segre, L Smith Eds., Marcel Dekker, Inc., New York
      and Basel, 1988, p. 295-330.
  4. Song LJ, Kim Y, Chopra RK, Proust JJ, Nagel JE, Nordin AA, Adler WH. Age related
      effects in T cell activation and proliferation. Exp Gerontol 1993; 28: 313-321.
  5. Zhou D, Chrest FJ, Adler WH, Munster A, Winchurch R. Increased production of TGF beta
      and Il-6 by aged spleen cells. Immunol Lett 1993;36:7-12.
  6. Radl J. Age-related monoclonal gammopathies: Clinical lessons from the aging C58Bl mouse.
      Immunology Today 1990; 11: 234.
  7. Silvestris F. et al. Discrepancy in the expression of autoantibodies in healthy aged individuals.
      Clinical Immunology and Immunopathology 1985; 35: 234
  8. Adler WH, Song LJ, Chopra RK, Winchurch RA, Waggie KS, Nagel JE. Immune
      Deficiency of Aging. In Aging, Immunity, and Infection, DC Powers, JE Morley and RM Coe
      Eds., Springer Publishing Co. New York 1994; 66-81.
  9. Chrest FJ, Pyle RS, Schoonmaker MM, Nagel JE, Adler WH. Age and gender differences
      in human CD19+ and CD19+/CD 23+ peripheral blood B lymphocytes. Aging Immunol Inf
      Dis 1993; 4: 231-244.
 
 Return To Contents